Fatal myelodysplastic syndrome developing during therapy with imatinib mesylate and characterised by the emergence of complex Philadelphia negative clones.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

12 citing papers in PubMed, 30 citations in OpenAlex.

1. [Philadelphia chromosome-negative myeloid neoplasms in patients with Philadelphia chromosome-positive chronic myeloid leukemia during tyrosine kinase inhibtor-therapy].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2019
   Article
2. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis.Journal of hematology & oncology · 2015
   Article
3. Philadelphia chromosome-negative acute myeloid leukemia with 11q23/MLL translocation in a patient with chronic myelogenous leukemia.Stem cell investigation · 2015
   Article
4. Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.BMC blood disorders · 2010
   Article
5. Emergence of abnormal clone with monsomy 7 in Philadelphia negative cells of CML patients treated with tyrosine kinase inhibitors.International journal of hematology · 2009
   Article
6. Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.Leukemia research · 2008
   Article
7. Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.Current hematologic malignancy reports · 2006
   Review
8. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL.Leukemia · 2006
   Article
9. Ph-positive and -negative myeloproliferative syndromes may co-exist.Leukemia · 2004
   Article
10. Clonal evolution in Philadelphia chromosome negative cells following successful treatment with Imatinib of a CML patient: clinical and biological features of a myelodysplastic syndrome.Leukemia · 2004
    Article
11. Philadelphia-negative acute lymphoblastic leukemia developing in a CML patient in imatinib mesylate-induced complete cytogenetic remission.Leukemia · 2003
    Review
12. Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.Leukemia · 2003
    Article

Corrections and comments

• Commented on by
  Myelodysplastic features developing in Philadephia-negative cells during imatinib mesylate therapy for CML: report of a new case.2003
• Comment on
  Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8.2002

Authors and funding

5 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as